aTyr Pharma Inc (LIFE)
1.65
+0.04
(+2.48%)
USD |
NASDAQ |
May 06, 16:00
1.65
0.00 (0.00%)
After-Hours: 20:00
aTyr Pharma Cash from Financing (Quarterly): 6.034M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 6.034M |
| September 30, 2023 | 2.682M |
| June 30, 2023 | 8.018M |
| March 31, 2023 | 49.50M |
| December 31, 2022 | 0.918M |
| September 30, 2022 | 3.013M |
| June 30, 2022 | 0.039M |
| March 31, 2022 | 1.481M |
| December 31, 2021 | 0.028M |
| September 30, 2021 | 83.87M |
| June 30, 2021 | 1.271M |
| March 31, 2021 | 24.86M |
| December 31, 2020 | 0.999M |
| September 30, 2020 | 0.334M |
| June 30, 2020 | -1.969M |
| March 31, 2020 | 16.78M |
| December 31, 2019 | -1.995M |
| September 30, 2019 | -0.122M |
| June 30, 2019 | 4.072M |
| March 31, 2019 | -0.619M |
| Date | Value |
|---|---|
| December 31, 2018 | -1.613M |
| September 30, 2018 | -1.994M |
| June 30, 2018 | -0.639M |
| March 31, 2018 | 0.008M |
| December 31, 2017 | 5.162M |
| September 30, 2017 | 42.50M |
| June 30, 2017 | 5.04M |
| March 31, 2017 | 0.001M |
| December 31, 2016 | 7.149M |
| September 30, 2016 | -0.86M |
| June 30, 2016 | -0.765M |
| March 31, 2016 | -0.827M |
| December 31, 2015 | -1.097M |
| September 30, 2015 | -0.784M |
| June 30, 2015 | 104.73M |
| March 31, 2015 | 45.07M |
| December 31, 2014 | -1.785M |
| September 30, 2014 | -0.773M |
| June 30, 2014 | 5.057M |
| March 31, 2014 | 0.013M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.995M
Minimum
Dec 2019
83.87M
Maximum
Sep 2021
10.52M
Average
1.481M
Median
Mar 2022
Cash from Financing (Quarterly) Benchmarks
| Vaxart Inc | -0.066M |
| Allogene Therapeutics Inc | 0.155M |
| AIM ImmunoTech Inc | 0.147M |
| Protalix BioTherapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | -0.043M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -11.06M |
| Cash from Investing (Quarterly) | 17.82M |
| Free Cash Flow | -37.44M |
| Free Cash Flow Per Share (Quarterly) | -0.1868 |
| Free Cash Flow Yield | -42.36% |